Ab­b­Vie eyes Hu­mi­ra match­ing move in­to pso­ri­at­ic arthri­tis for im­munol­o­gy fol­low-up Skyrizi

Phar­ma borg Ab­b­Vie hasn’t had many road­blocks on its path to dom­i­nance with megablock­buster Hu­mi­ra reg­u­lar­ly top­ping phar­ma’s best­seller list. But Hu­mi­ra’s days on top are num­bered, and Ab­b­Vie is mak­ing the case for new­er im­munol­o­gy meds like IL-23 Skyrizi to help take the sting out of a cost­ly 2023 patent cliff.

Help­ing that cause, Skyrizi best­ed place­bo in terms of re­duc­ing pso­ri­at­ic arthri­tis pa­tients’ symp­toms from base­line af­ter six months of treat­ment, ac­cord­ing to da­ta from two Phase III tri­als un­veiled Tues­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.